Jul. 4—MORGANTOWN — The tangled world of generic pharmaceuticals took another twist last week, as Mylan Pharmaceuticals filed suit in federal court against Israel-based Teva, alleging Teva illegally ...

FDA is widely known to be considering the approval of a generic version of Teva Pharmaceutical’s (NYSE:TEVA) blockbuster drug for multiple sclerosis, Copaxone. The patents covering Copaxone for its ...

Teva’s fight to keep generic Copaxone off the market hit a snag Friday when the Supreme Court said it would not allow an injunction to go forward while the drugmaker waited for the appeals process to ...

Israel-based Teva Pharmaceutical is one of the largest global generic drug manufacturers, with a significant presence in the United States and in Western Europe. Generic drug manufacturers with large ...

Teva's strategy for padding its Copaxone franchise even in the face of generic competition just took a major hit. The company lost its bid to defend the long-acting, 40mg version of the multiple ...

TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone before 2014, the company's president and chief executive said in ...

A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

Teva’s push to keep generic Copaxone off the market its over. Bloomberg reports the company lost its suit to keep generics at bay, just 10 days before the expiration of the branded MS drug’s patent.

NEW YORK--(BUSINESS WIRE)--The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at Teva Pharmaceutical Industries Ltd., according to Fitch Ratings.

To say that Momenta Pharmaceuticals has been beaten down by Mr. Market in 2014 would be an understatement. The developmental-stage biotech has lost a lot of value since the beginning of the year ...